期刊
MOLECULES
卷 26, 期 17, 页码 -出版社
MDPI
DOI: 10.3390/molecules26175406
关键词
peptidomimetics; designed multiple ligand; peptide; mu-opioid receptor; delta-opioid receptor; opioid agonist; neurokinin; NK2; NK3; antinociception
资金
- Research Council of VUB [SRP50]
Opioid agonists are commonly used for pain relief, but their side effects can be problematic. Designed multiple ligands (DMLs) offer a promising approach by targeting both opioid and non-opioid pathways involved in pain perception. Newly designed opioid agonist-NK2 or -NK3 antagonists show potential for future opioid hybrid development.
Opioid agonists are well-established analgesics, widely prescribed for acute but also chronic pain. However, their efficiency comes with the price of drastically impacting side effects that are inherently linked to their prolonged use. To answer these liabilities, designed multiple ligands (DMLs) offer a promising strategy by co-targeting opioid and non-opioid signaling pathways involved in nociception. Despite being intimately linked to the Substance P (SP)/neurokinin 1 (NK1) system, which is broadly examined for pain treatment, the neurokinin receptors NK2 and NK3 have so far been neglected in such DMLs. Herein, a series of newly designed opioid agonist-NK2 or -NK3 antagonists is reported. A selection of reported peptidic, pseudo-peptidic, and non-peptide neurokinin NK2 and NK3 ligands were covalently linked to the peptidic mu-opioid selective pharmacophore Dmt-DALDA (H-Dmt-d-Arg-Phe-Lys-NH2) and the dual mu/delta opioid agonist H-Dmt-d-Arg-Aba-beta Ala-NH2 (KGOP01). Opioid binding assays unequivocally demonstrated that only hybrids SBL-OPNK-5, SBL-OPNK-7 and SBL-OPNK-9, bearing the KGOP01 scaffold, conserved nanomolar range mu-opioid receptor (MOR) affinity, and slightly reduced affinity for the delta-opioid receptor (DOR). Moreover, NK binding experiments proved that compounds SBL-OPNK-5, SBL-OPNK-7, and SBL-OPNK-9 exhibited (sub)nanomolar binding affinity for NK2 and NK3, opening promising opportunities for the design of next-generation opioid hybrids.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据